

Date: 11th November, 2018

To,
Listing Department,
BSE Limited
Floor 25, PJ Tower
Dalal Street,
Mumbai - 400 001
Script Code: 540359

- Sub.: 1. Unaudited Financial Results for the quarter and half year ended 30th September, 2018.**
- 2. Limited Review Report for the quarter and half year ended 30th September, 2018.**

Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 11th November, 2018, inter-alia, considered and approved the Unaudited Financial Results for quarter and half year ended 30th September, 2018. The same has also been reviewed by the Audit Committee in its meeting held today.


A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2018, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 1:00 p.m. and concluded at 7:00 p.m.

Further, we would like to submit that M/s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter & half year ended 30th September, 2018 and Board has also taken on record their Limited Review Report on said Results.

For Parmax Pharma Limited

Alkesh R. Gosalia

Alkesh R. Gosalia
Din: 01130615
Director



Statement of Standalone Unaudited Results for the Quarter & Half year ended 30.09.2018

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	35350685	33827442	33719949	69178127	59781662	119015986
II.	Other income	44316	42594	44371	86910	245251	472423
III.	Total Income (I+II)	35395001	33870036	33764320	69265037	60026913	119488409
IV.	Expenses						
	(a) Cost of materials consumed	12823730	15243666	13736054	28067396	38559704	70645775
	(b) Purchase of stock-in-trade	0	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	13093023	2712514	6674743	15805537	-1802888	-12830395
	(d) Employee benefits expense	5214196	4904966	6942345	10119162	12032627	21313498
	(e) Finance Costs	271569	65114	186881	336683	186881	335776
	(f) Depreciation and amortisation expense	2595337	2552100	2724000	5147437	5211000	10929861
	(g) Other expenses	6941907	7777540	4601075	14719447	9031879	29077352
	Total expenses (IV)	40939762	33255900	34865098	74195662	63219203	119471867
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-5544761	614136	-1100778	-4930625	-3192290	16542
VI	Exceptional Items	0	0	0	0	0	0
VII	Profit/ (Loss) before tax (V-VI)	-5544761	614136	-1100778	-4930625	-3192290	16542
VIII	Tax expense:						
	(1) Current tax	0	0	0	0	0	250000
	(2) Deferred tax	0	0	0	0	0	238884
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-5544761	614136	-1100778	-4930625	-3192290	5426
X	Profit/(loss) from discontinued operations						
XI	Tax expense of discontinued operations	0	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XIII	Profit (Loss) for the period (IX+XII)	-5544761	614136	-1100778	-4930625	-3192290	5426
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-5544761	614136	-1100778	-4930625	-3192290	5426
XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-1.48	0.16	-0.29	-1.32	-0.85	0.00
	(b) Diluted	-	-	-	-	-	-

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 11.11.2018.
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2018
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2018, in the prescribed format under Schedule III of Companies Act, 2013
5. The figures for the previous period have been regrouped wherever necessary.

FOR, PARMAX PHARMA LIMITED

A.A. Gosalia


Alkesh Gosalia
Director



Place Hadamtala (Rajkot)
Date: 11.11.2018

Statement of Assets and Liabilities as at 30.09.2018			
Sr. No.	Particulars	As at 30.09.2018 (Unaudited)	As at 31.03.2018 (Audited)
I.	Assets		
1	Non-current assets		
	(a) Property, Plant and Equipment	54093369	58626140
	(b) Capital work-in-progress	22330846	0
	(c) Investment Property	0	0
	(d) Goodwill	0	0
	(e) Other Intangible assets	0	0
	(f) Intangible assets under development	0	0
	(g) Biological Assets other than bearer plants	0	0
	(h) Financial Assets	0	0
	(i) Investments	6000	6000
	(j) Trade receivables	0	0
	(k) Loans	780699	780699
	(l) Deferred tax assets (net)	238884	0
	(m) Other non-current assets	18730187	15492466
	Total Non-Current Assets	96179985	74905305
2	Current assets		
	(a) Inventories	12608452	32178226
	(b) Financial Assets	0	0
	(i) Investments	0	0
	(ii) Trade receivables	21874699	19720057
	(iii) Cash and cash equivalents	1285754	9576862
	(iv) Bank balances other than (iii) above	0	0
	(v) Loans	12034955	29644061
	(vi) Others (to be specified)	0	0
	(c) Current Tax Assets (Net)	0	0
	(d) Other current assets	8368676	0
	Total Current Assets	56172536	91119206
	Total Assets	152352521	166024510
II.	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	44511500	44511500
	(b) Other Equity	-3875962	1065775
	Total Equity	40635538	45577275
2	LIABILITIES		
i.	Non-current liabilities		
	(a) Financial Liabilities	0	0
	(i) Borrowings	14066569	21624233
	(ii) Trade payables	0	0
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0	0
	(b) Provisions	0	0
	(c) Deferred tax liabilities (Net)	0	0
	(d) Other non-current liabilities	51800	0
	Total of Non-Current Liabilities	14118369	21624233
ii.	Current liabilities		
	(a) Financial Liabilities	0	0
	(i) Borrowings	976411	0
	(ii) Trade payables	94204991	96484318
	(iii) Other financial liabilities (other than those specified in item (c))	0	0
	(b) Other current liabilities	1841143	105131
	(c) Provisions	328750	2233551
	(d) Current Tax Liabilities (Net)	247319	0
	Total of Current Liabilities	97598614	98823000
	Total Equity and Liabilities	152352521	166024510

FOR PARMAX PHARMA LIMITED

Place: Hadamtala (Rajkot)
Date: 11.11.2018Alkesh R. Gosalia
Director

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax : +91-2827-270536 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

Partner
Malay B Shah
B.Com. A.C.A.

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

M.No. 038000

M. No. 159526

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended 30th September 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 11th November 2018. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRS:) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the



Head Office:

209-Sapphire Complex, IInd Floor,
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. A.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 11.11.2018



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants

A handwritten signature in blue ink that reads "Malay B. Shah".

MALAY B SHAH
Partner
M. No. 159526

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD – 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com